'One Of Best-In-Class' Cannabis MSOs Has 'Optionality' When States Go Recreational, Bullish Analyst Says After Results

Cresco Labs Inc. CL CRLBF reported its financial results on Wednesday for the second quarter of fiscal 2022, revealing a 4% year-over-year increase in revenue to $218 million.

The transaction with Columbia Care Inc. CCHWF CCHW CCHW 3LP is proceeding as expected,” Charles Bachtell, the company’s CEO and co-founder, said in a press release adding that “the divestiture and regulatory processes are on track and we continue to anticipate a closing around year-end.”

Cantor Fitzgerald’s analyst Pablo Zuanic addressed the company’s earnings in his recent note, highlighting that that sequential revenue growth of 2% was below his estimate.

The Analyst                           

Zuanic retained Overweight ratings on both Cresco’s and Columbia Care's stocks but lowered his 12-month price target for Cresco to $15 from $19 due to the reduced estimates, and disclosed a price target for Columbia of $8.37, up from $5.10.

The Thesis

The analyst said the slight quarter-over-quarter revenue increase is “understandable” if taking into account Cresco’s footprint and the fact that none of those states will go recreational in the second half of 2022.

However, he added that the ”stock has optionality from several states in the east potentially going rec in the coming years.”

Commenting on the deal to acquire its rival Columbia Care for $2.1 billion, which was announced in March, Zuanic said Cresco is now focused on closing the transaction, adding that “divestitures from the merger are seen raising gross proceeds north of $300 million.”

The company “runs one of the best-in-class operations in the MSO space,” the analyst said, referring to its revenue, store count as well as wholesale presence, and presence in key states.

CRLBF Price Action

Cresco’s shares traded $3.2% lower at $3.63 per share at the market close on Wednesday.

CCHWF Price Action

Columbia Care's shares traded 3.19% lower at $1.82 per share at the market close on Wednesday.

Benzinga Cannabis Capital Conference

Come and meet Pablo Zuanic, Charles Bachtell, and other extraordinary cannabis visionaries at the Benzinga Cannabis Capital Conference, which returns this fall in Chicago and stay at the historic Palmer House Hotel. Don't miss out on a chance to hear about future market forecasts and worldly advice on investing and finance from those embedded in the cannabis industry.

Book your tickets HERE, and your room HERE.

sept_2022_ccc_1200x800_0.png

Photo: Courtesy of gerald by Pixabay

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorCannabisEarningsNewsPenny StocksSmall CapMarketsCantor FitzgeraldCharles BachtellPablo Zuanicsecond quarter earningsstock analysis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.